These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 23657428)

  • 1. Pharmacogenetics of warfarin: challenges and opportunities.
    Lee MT; Klein TE
    J Hum Genet; 2013 Jun; 58(6):334-8. PubMed ID: 23657428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of a proposed warfarin dosing algorithm based on the genetic make-up of Egyptian patients.
    Ekladious SM; Issac MS; El-Atty Sharaf SA; Abou-Youssef HS
    Mol Diagn Ther; 2013 Dec; 17(6):381-90. PubMed ID: 23839801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and comparison of a warfarin-dosing algorithm for Korean patients with atrial fibrillation.
    Cho HJ; On YK; Bang OY; Kim JW; Huh W; Ko JW; Kim JS; Lee SY
    Clin Ther; 2011 Oct; 33(10):1371-80. PubMed ID: 21981797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenetics of oral anticoagulants: a basis for dose individualization.
    Stehle S; Kirchheiner J; Lazar A; Fuhr U
    Clin Pharmacokinet; 2008; 47(9):565-94. PubMed ID: 18698879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Warfarin Pharmacogenetics: New Life for an Old Drug.
    Wen MS; Lee MT
    Acta Cardiol Sin; 2013 May; 29(3):235-42. PubMed ID: 27122712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing.
    Johnson JA; Gong L; Whirl-Carrillo M; Gage BF; Scott SA; Stein CM; Anderson JL; Kimmel SE; Lee MT; Pirmohamed M; Wadelius M; Klein TE; Altman RB;
    Clin Pharmacol Ther; 2011 Oct; 90(4):625-9. PubMed ID: 21900891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Warfarin pharmacogenetics: does more accurate dosing benefit patients?
    Eby C
    Semin Thromb Hemost; 2012 Oct; 38(7):661-6. PubMed ID: 23047421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence for a pharmacogenetic adapted dose of oral anticoagulant in routine medical practice.
    Becquemont L
    Eur J Clin Pharmacol; 2008 Oct; 64(10):953-60. PubMed ID: 18758764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective evaluation of a pharmacogenetics-guided warfarin loading and maintenance dose regimen for initiation of therapy.
    Gong IY; Tirona RG; Schwarz UI; Crown N; Dresser GK; Larue S; Langlois N; Lazo-Langner A; Zou G; Roden DM; Stein CM; Rodger M; Carrier M; Forgie M; Wells PS; Kim RB
    Blood; 2011 Sep; 118(11):3163-71. PubMed ID: 21725053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacogenetics of Warfarin Therapy.
    Ruff CT
    Clin Chem; 2018 Nov; 64(11):1558-1559. PubMed ID: 29941467
    [No Abstract]   [Full Text] [Related]  

  • 11. Warfarin pharmacogenetics: to genotype or not to genotype, that is the question.
    Cavallari LH; Nutescu EA
    Clin Pharmacol Ther; 2014 Jul; 96(1):22-4. PubMed ID: 24942399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Warfarin pharmacogenetics.
    Limdi NA; Veenstra DL
    Pharmacotherapy; 2008 Sep; 28(9):1084-97. PubMed ID: 18752379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study.
    Carlquist JF; Horne BD; Muhlestein JB; Lappé DL; Whiting BM; Kolek MJ; Clarke JL; James BC; Anderson JL
    J Thromb Thrombolysis; 2006 Dec; 22(3):191-7. PubMed ID: 17111199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Application of warfarin pharmacogenetics].
    Tomek A; Mat'oska V; Kumstýrfová T; Táborský L
    Vnitr Lek; 2009 Jun; 55(6):565-9. PubMed ID: 19662888
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Understanding the pharmacogenetic approach to warfarin dosing.
    Glurich I; Burmester JK; Caldwell MD
    Heart Fail Rev; 2010 May; 15(3):239-48. PubMed ID: 18998206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of genetic factors for warfarin dose prediction.
    Caldwell MD; Berg RL; Zhang KQ; Glurich I; Schmelzer JR; Yale SH; Vidaillet HJ; Burmester JK
    Clin Med Res; 2007 Mar; 5(1):8-16. PubMed ID: 17456829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genotypes of vitamin K epoxide reductase, gamma-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients.
    Kimura R; Miyashita K; Kokubo Y; Akaiwa Y; Otsubo R; Nagatsuka K; Otsuki T; Okayama A; Minematsu K; Naritomi H; Honda S; Tomoike H; Miyata T
    Thromb Res; 2007; 120(2):181-6. PubMed ID: 17049586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Warfarin pharmacogenetics: development of a dosing algorithm for Omani patients.
    Pathare A; Al Khabori M; Alkindi S; Al Zadjali S; Misquith R; Khan H; Lapoumeroulie C; Paldi A; Krishnamoorthy R
    J Hum Genet; 2012 Oct; 57(10):665-9. PubMed ID: 22854539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Possible application of pharmacogenomics to warfarin therapy].
    Murata M
    Rinsho Byori; 2011 Jun; 59(6):594-7. PubMed ID: 21815482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The pharmocogenomics of warfarin: closing in on personalized medicine.
    Rettie AE; Tai G
    Mol Interv; 2006 Aug; 6(4):223-7. PubMed ID: 16960144
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.